eCase Challenge 2: Managing the Risk of Hypoglycemia in Special Patient Populations
This self-assessment activity outlines risk factors and treatment options of managing hypoglycemia in patients with T2DM. Also available, eCase Challenge 1 and Monograph: Managing the Risk of Hypoglycemia in Special Patient Populations.

eCase Challenge 2: Managing the Risk of Hypoglycemia in Special Patient Populations

Lawrence Herman, MPA, PA-C, DFAAPA; Jill Ellis, MPA, PA-C

Selecting appropriate, while avoiding inappropriate, pharmacotherapy is vital to managing diabetes and preventing hypoglycemia. Not understanding the mechanisms of action of various treatment options and all the available options to choose from can have serious consequences for patients. Providers must understand what therapies are available, including their benefits, side effects, and mechanisms of action.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:
  • Identify risk factors for hypoglycemia in patients with T2DM and adjust existing therapy accordingly.
  • Distinguish risk factors, and comorbid conditions that may increase the risk of hypoglycemia and set individualized A1C treatment goals.
  • Select newer treatment options with a low risk of hypoglycemia.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 0.75 AAPA Category 1 Self-Assessment CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until December 31, 2018.

Responsibility Statement

AAPA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Faculty

Lawrence Herman, MPA, PA-C, DFAAPA
Visiting Faculty
University of Texas Medical Branch
Galveston, TX
Consultant: Novo Nordisk; Speaker’s Bureau – Novo Nordisk.

Jill Ellis, MPA, PA-C
PA Faculty Member
Assistant Professor
PA Studies
Grand Valley State University
Grand Rapids, MI
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Activity Planners

Michael Speidel, Jennifer Gregg, PhD and Joanne Jeffers, Medical Logix, LLC have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

AAPA Staff Activity Planner

Daniel Pace has no relationship with any commercial interests whose products or services may be mentioned during this presentation.

Off-Label/Unapproved Product(s) Discussion

There are no references to off-label/unapproved uses of products in this program.

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by independent educational grants from Merck and Novo Nordisk

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
484 Registered Users